DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 1 USDMF, 1 VMF, 1 Listed Suppliers

2 API Suppliers
1 USDMF
1 VMF
1 Listed Suppliers

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

RELATED EXCIPIENT COMPANIES

1 DKSH, 1 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 1 Doshion Polyscience, 1 Finar, 1 Gangwal Chemicals, 1 Sigachi Industries, 1 Valens Pharmachem

relatedExcipients
1 DKSH
1 Gangwal Healthcare
1 Nanjing Well Pharmaceutical
1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
1 BASF
1 Doshion Polyscience
1 Finar
1 Gangwal Chemicals
1 Sigachi Industries
1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

3 Emulsifying Agents, 3 Topical, 2 Lubricants & Glidants, 2 Film Formers & Plasticizers, 2 Direct Compression, 2 Solubilizers, 2 Thickeners and Stabilizers, 1 Controlled & Modified Release, 1 Parenteral, 1 Co-Processed Excipients, 1 Fillers, Diluents & Binders, 1 API Stability Enhancers, 1 Taste Masking

excipientsByApplications
3 Emulsifying Agents
3 Topical
2 Lubricants & Glidants
2 Film Formers & Plasticizers
2 Direct Compression
2 Solubilizers
2 Thickeners and Stabilizers
1 Controlled & Modified Release
1 Parenteral
1 Co-Processed Excipients
1 Fillers, Diluents & Binders
1 API Stability Enhancers
1 Taste Masking

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

MARKET PLACE

3 APIs

marketPlace
3 APIs

PATENTS & EXCLUSIVITIES

3 Health Canada Patents

patents
3 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM , 1 USP , 1 Others

otherSolutions
1 EDQM
1 USP
1 Others

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

1INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

10 RELATED EXCIPIENT COMPANIES

22EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 113617-63-3, Orbax, Nsc-758614, 660932tpy6, 1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic acid, 3-quinolinecarboxylic acid, 1-cyclopropyl-7-[(3r,5s)-3,5-dimethyl-1-piperazinyl]-5,6,8-trifluoro-1,4-dihydro-4-oxo-, rel-

Molecular Formula

C₁₉H₂₀F₃N₃O₃

Molecular Weight

395.4 g/mol

InChI Key

QIPQASLPWJVQMH-DTORHVGOSA-N

FDA UNII

660932TPY6

Orbifloxacin is a fluoroquinolone antibiotic. It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.

1 2D Structure

Orbifloxacin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic acid

2.1.2 InChI

InChI=1S/C19H20F3N3O3/c1-8-5-24(6-9(2)23-8)17-14(21)13(20)12-16(15(17)22)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6H2,1-2H3,(H,27,28)/t8-,9+

2.1.3 InChI Key

QIPQASLPWJVQMH-DTORHVGOSA-N

2.1.4 Canonical SMILES

CC1CN(CC(N1)C)C2=C(C3=C(C(=C2F)F)C(=O)C(=CN3C4CC4)C(=O)O)F

2.1.5 Isomeric SMILES

C[C@@H]1CN(C[C@@H](N1)C)C2=C(C3=C(C(=C2F)F)C(=O)C(=CN3C4CC4)C(=O)O)F

2.2 Other Identifiers

2.2.1 UNII

660932TPY6

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 113617-63-3

2. Orbax

3. Nsc-758614

4. 660932tpy6

5. 1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic Acid

6. 3-quinolinecarboxylic Acid, 1-cyclopropyl-7-[(3r,5s)-3,5-dimethyl-1-piperazinyl]-5,6,8-trifluoro-1,4-dihydro-4-oxo-, Rel-

7. Ncgc00160518-01

8. Dsstox_cid_26201

9. Dsstox_rid_81432

10. Dsstox_gsid_46201

11. 1-cyclopropyl-7-((3s,5r)-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

12. 1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic Acid

13. Smr000544203

14. Cp-104354

15. Orbifloxacin [inn]

16. Cas-113617-63-3

17. Sr-01000790054

18. Orbifloxacin [usp:inn:ban]

19. Mfcd00864858

20. Unii-660932tpy6

21. 1-cyclopropyl-7-((3r,5s)-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

22. Specplus_000366

23. Cp 104354

24. Orbifloxacin (usp/inn)

25. Orbifloxacin [mi]

26. Orbax [veterinary] (tn)

27. Orbifloxacin [jan]

28. Orbifloxacin Impurity Mixture

29. Orbifloxacin [mart.]

30. Mls000766847

31. Mls001216436

32. Divk1c_006462

33. Orbifloxacin [usp-rs]

34. Schembl125116

35. Chembl295433

36. Dtxsid7046201

37. Kbio1_001406

38. Orbifloxacin [green Book]

39. Chebi:183823

40. Hms2875g03

41. Hms3264m13

42. Pharmakon1600-01503711

43. Orbifloxacin [usp Impurity]

44. Bcp18829

45. Hy-b0915

46. Rkl10078

47. Zinc3882891

48. Orbifloxacin [usp Monograph]

49. Tox21_111867

50. Nsc758614

51. S4150

52. Akos015969739

53. Tox21_111867_1

54. Ccg-213832

55. Cs-4384

56. Db11443

57. Ks-5013

58. Nsc 758614

59. Orbifloxacin 100 Microg/ml In Methanol

60. Ncgc00160518-02

61. Ncgc00160518-03

62. Ncgc00160518-04

63. 1-cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxo-quinoline-3-carboxylic Acid

64. Sbi-0207085.p001

65. Orbifloxacin 100 Microg/ml In Acetonitrile

66. O0516

67. D08299

68. D91881

69. O-2950

70. Ab00833179_04

71. Ab00833179_05

72. Orbifloxacin, Vetranal(tm), Analytical Standard

73. A803076

74. Orbifloxacin, Antibiotic For Culture Media Use Only

75. Q7100015

76. Sr-01000790054-2

77. Sr-01000790054-3

78. Brd-k63001556-001-03-9

79. Orbifloxacin, European Pharmacopoeia (ep) Reference Standard

80. Orbifloxacin, United States Pharmacopeia (usp) Reference Standard

81. 1-cyclopropyl-5,6,8-trifluoro-7-(cis-3,5-dimethyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid

82. 1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-5,6,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid

83. 1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-5,6,8-trifluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid

84. 1-cyclopropyl-7-(cis-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

85. 1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxo-quinoline-3-carboxylic Acid

86. 1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-4-ium-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylate

87. 1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-5,6,8-triluoro-4-oxoquinoline-3-carboxylic Acid

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₂₀F₃N₃O₃
Molecular Weight	395.4 g/mol
XLogP3	0.9
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	3
Exact Mass	395.14567599 g/mol
Monoisotopic Mass	395.14567599 g/mol
Topological Polar Surface Area	72.9 Å²
Heavy Atom Count	28
Formal Charge	0
Complexity	691
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1